A CASE OF EUGLYCAEMIC DIABETIC KETOACIDOSIS IN A PATIENT TREATED WITH CANAGLIFLOZIN

Dr Katherine Hudson, Dr Nida Pasha, Dr Edel Casey, Dr Gangani Yokandawala, Dr Eltayeb Marouf, Dr Nemanja Stojanovic

1 Department of Endocrinology, Queen’s Hospital, Romford; 2 Department of Endocrinology, King George Hospital, Ilford; Intensive Care Unit, King George Hospital, Ilford

Abstract

Background: Canagliflozin is an oral hypoglycaemic agent from the novel class of Sodium Glucose Co-Transporter 2 (SGLT-2) inhibitors, used in the treatment of patients with Type 2 Diabetes Mellitus (T2DM). Although effective in the treatment of hyperglycaemia, these medications have been linked to the development of diabetic ketoacidosis (DKA). We describe the case of a patient with T2DM who presented with severe metabolic acidosis while taking Canagliflozin.

Case: We report the case of a 43-year-old Caucasian male with T2DM who presented with vomiting, dehydration, fatigue and abdominal pain. He had been prescribed Canagliflozin four months earlier.

The patient was found to have a severe metabolic acidosis, with high urinary ketones but normal blood glucose levels. He was haemodynamically stable at presentation, and remained so throughout admission. Treatment with intravenous insulin, fluids and sodium bicarbonate resolved the acidosis, and canagliflozin was stopped.

Discussion: SGLT-2 inhibitors prevent glucose resorption from urine, leading to increased urinary glucose clearance and subsequent improvement of glycaemic control. Nonetheless, in May 2015, the FDA published a safety warning for this class of drugs, reporting over 20 cases of DKA in patients taking the medication. It is important for clinicians and patients to be aware of the potential risk of euglycaemic DKA in patients taking SGLT2 inhibitors. Acute illness, dehydration and relative insulinopenia may predispose some patients. Whether supplying patients prescribed these medications with ketone meters could help prevent DKA, or lead to earlier admissions, merits further research.

Introduction

Canagliflozin, of the Sodium Glucose Co-Transporter 2 (SGLT-2) inhibitors class of oral hypoglycaemic agents, is used in the treatment of Type 2 Diabetes Mellitus (T2DM). SGLT2 inhibitors work by lowering the renal threshold for glucose excretion, resulting in a greater urinary excretion of glucose. Canagliflozin was approved for use in both the EU and USA in 2013.

In May 2015, the FDA published a safety warning3 for SGLT2 inhibitors, reporting over twenty cases of diabetic ketoacidosis (DKA) in patients taking the medication. We report the case of a 43-year-old Caucasian male who presented to A&E four months following initiation of treatment with canagliflozin.

The Case

The patient was a 43-year-old Caucasian male with T2DM. His blood glucose levels were previously well controlled with metformin, sitagliptin, gliclazide and canagliflozin. His BMI was 21.8. He was haemodynamically stable at presentation, and throughout his admission.

Symptoms:

- Three days of fatigue, loss of appetite, and generalised aches and pains
- One episode of vomiting on the day of presentation
- Several episodes of diarrhoea days earlier, with severe right-sided abdominal pain on the day of presentation. He also reported symptoms that were in keeping with ileus.

References


To our knowledge this is the first reported case in the UK of a patient presenting with euglycaemic DKA caused by treatment with SGLT-2 inhibitors.

Cases of euglycaemic diabetic ketoacidosis (eDKA) have been reported in patients taking canagliflozin4-5. Increased urinary excretion of glucose lowers plasma glucose levels, and predisposes the patient to a ketogenic state. Since blood glucose levels are within range, and unless patients monitor ketone levels, they may not seek medical attention despite feeling profoundly unwell. Predisposing factors are thought to include acute illness, dehydration, periods of fasting, and relative insulinopenia3.

It is important for both clinicians and patients to be aware of the risk of eDKA when taking SGLT-2 inhibitors, as acidosis may develop insidiously. Provision of ketone-meters to patients prescribed this class of medication may prevent development of eDKA, or lead to earlier admissions to hospital. This warrants further research. Patients should be educated about the risks of taking an SGLT-2 inhibitor, and the possibility that they may become unwell while still having an acceptable plasma glucose.

Discussion